Patents by Inventor John C. Zwaagstra
John C. Zwaagstra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101641Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-?) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.Type: ApplicationFiled: August 29, 2023Publication date: March 28, 2024Applicant: National Research Council of CanadaInventors: Anne E.G. LENFERINK, John C. Zwaagstra, Traian Sulea, Maureen D. O'Connor-McCourt
-
Patent number: 11866481Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-?) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.Type: GrantFiled: March 1, 2018Date of Patent: January 9, 2024Assignee: National Research Council of CanadaInventors: Anne E. G. Lenferink, John C. Zwaagstra, Traian Sulea, Maureen D. O'Connor-McCourt
-
Publication number: 20220204587Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-?) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.Type: ApplicationFiled: March 1, 2018Publication date: June 30, 2022Inventors: Anne E.G. LENFERINK, John C. ZWAAGSTRA, Traian SULEA, Maureen D. O'CONNOR-MCCOURT
-
Publication number: 20220169702Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-beta) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.Type: ApplicationFiled: November 10, 2021Publication date: June 2, 2022Applicant: National Research Council of CanadaInventors: John C. Zwaagstra, Traian Sulea, Maria L. Jaramillo, Maureen D. O'Connor, Anne E.G. Lenferink
-
Publication number: 20220162337Abstract: The present invention is directed to anti-Her2 antibodies and fragments thereof, compositions, and uses thereof. The antibodies and fragments thereof bind to Her2-expressing cells in a pH-dependent manner, with low affinity at the physiological pH typical of normal cells and tissues, and with high affinity at the slightly acidic pH characteristic to solid tumors. Furthermore, the antibodies inhibit the growth of tumor spheroids at a level comparable to that of the benchmark anti-Her2 antibody Herceptin at acidic pH, whereas these effects were significantly reduced at physiological pH. This pH selectivity of cellular growth inhibition is maintained upon antibody conjugation to cytotoxic drugs. The invention also includes methods of treating solid tumors, methods of detecting solid tumors, and methods of pH-dependent capturing of the Her-2 ectodomain.Type: ApplicationFiled: March 30, 2020Publication date: May 26, 2022Applicant: National Research Council of CanadaInventors: Traian Sulea, Jason Baardsnes, Christopher R. Corbeil, Maria L. Jaramillo, Enrico O. Purisima, John C. Zwaagstra, Nazanin Larijani Rohani
-
Publication number: 20200231652Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-beta) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.Type: ApplicationFiled: August 31, 2016Publication date: July 23, 2020Applicant: National Research Council of CanadaInventors: John C. Zwaagstra, Traian Sulea, Maria Jaramillo, Maureen D. O'Connor, Anne E.G. Lenferink
-
Patent number: 8987417Abstract: The present invention addresses limitations of prior art receptor-based traps through a methodology called the clamp/click/cleave (CCC) approach. Two fusion proteins each comprising a binding domain fused to a coiled-coil are non-covalently dimerized through the coiled-coil (clamp), and the dimer so formed is stabilized by a covalent disulphide bond (click) between cysteine residues located on the fusion proteins between the binding domains and coiled-coils. Once the disulphide bond has formed, the coiled-coils are subsequently removed (cleave) by cleaving the fusions proteins at cleavage sites located between the cysteine residues and the coiled-coils to provide the covalently dimerized bivalent binding agent of the present invention. Such binding agents are useful in the treatment and diagnosis of disease states characterized by production and/or overexpression of a ligand to which the binding domains bind.Type: GrantFiled: November 28, 2011Date of Patent: March 24, 2015Assignee: National Research Council of CanadaInventors: John C. Zwaagstra, Maureen D. O'Connor-McCourt, Traian Sulea, Catherine Collins, Myriam Banville, Maria L. Jaramillo
-
Patent number: 8734760Abstract: The invention provides multivalent ligand binding agents (traps) for members of the TGF-? superfamily and polypeptide linkers and methods for making and using such constructs. The traps may be used as therapeutic or diagnostic (imaging or non-imaging) agents for diseases/disorders caused by over-production/activity of the target ligand. In an embodiment of the invention there is provided a multivalent binding agent with affinity for a member of the TGF-? superfamily, the agent having the general structure I: (<bd1>-linker1)k-[{<bd1>-linker2-<bd2>-linker3f-}n-(<bd3>)m-(linker4-<bd4>)d]h, where: n and h are independently greater than or equal to 1; d, f, m and k are independently equal to or greater than zero; bd's are polypeptide binding domains having an affinity for the same member of the TGF-? superfamily; and, linkers are unstructured polypeptide sequences.Type: GrantFiled: October 18, 2012Date of Patent: May 27, 2014Assignee: National Research Coucil of CanadaInventors: Maureen D. O'Connor-McCourt, Traian Sulea, John C. Zwaagstra, Jason Baardsnes
-
Patent number: 8658135Abstract: The invention provides hetero-multivalent ligand binging agents (traps) for members of the TGF-? superfamily, as well as methods for making and using such constructs. In an embodiment of the invention there is provided a hetero-multivalent binding agent with affinity for a member of the TGF-? superfamily. The agent comprises the general structure I: (<bd1>-linker1)k-[{<bd1>-linker2-<bd2>-linker3f-}n-(<bd3>)m-(linker4-<bd4>)d]h, where bd1, bd2, bd3 and bd4 are polypeptide binding domains having an affinity for different sites on the same member or for different members of the TGF-? superfamily; at least two of bd1, bd2, bd3, and bd4 are different from each other.Type: GrantFiled: September 17, 2009Date of Patent: February 25, 2014Assignee: National Research Council of CanadaInventors: Maureen D. O'Connor-McCourt, Traian Sulea, John C. Zwaagstra, Jason Baardsnes, Catherine Collins
-
Patent number: 8574548Abstract: The invention provides multivalent ligand binding agents (traps) for members of the TGF-? superfamily and polypeptide linkers and methods for making and using such constructs. The traps may be used as therapeutic or diagnostic (imaging or non-imaging) agents for diseases/disorders caused by over-production/activity of the target ligand. In an embodiment of the invention there is provided a multivalent binding agent with affinity for a member of the TGF-? superfamily, the agent having the general structure I: (<bd1>-linker1)k-[{<bd1>-linker2-<bd2>-linker3f-}n-(<bd3>)m-(linker4-<bd4>)d]h, where: n and h are independently greater than or equal to 1; d, f, m and k are independently equal to or greater than zero; bd's are polypeptide binding domains having an affinity for the same member of the TGF-? superfamily; and, linkers are unstructured polypeptide sequences.Type: GrantFiled: October 18, 2012Date of Patent: November 5, 2013Assignee: National Research Council of CanadaInventors: Maureen D. O'Connor-McCourt, Traian Sulea, John C. Zwaagstra, Jason Baardsnes
-
Publication number: 20130251712Abstract: The present invention addresses limitations of prior art receptor-based traps through a methodology called the clamp/click/cleave (CCC) approach. Two fusion proteins each comprising a binding domain fused to a coiled-coil are non-covalently dimerized through the coiled-coil (clamp), and the dimer so formed is stabilized by a covalent disulphide bond (click) between cysteine residues located on the fusion proteins between the binding domains and coiled-coils. Once the disulphide bond has formed, the coiled-coils are subsequently removed (cleave) by cleaving the fusions proteins at cleavage sites located between the cysteine residues and the coiled-coils to provide the covalently dimerized bivalent binding agent of the present invention. Such binding agents are useful in the treatment and diagnosis of disease states characterized by production and/or overexpression of a ligand to which the binding domains bind.Type: ApplicationFiled: November 28, 2011Publication date: September 26, 2013Applicant: National Research Council of CanadaInventors: John C. Zwaagstra, Maureen D. O'Connor-McCourt, Traian Sulea, Catherine Collins, Myriam Banville, Maria L. Jaramillo
-
Publication number: 20130089499Abstract: The invention provides multivalent ligand binding agents (traps) for members of the TGF-? superfamily and polypeptide linkers and methods for making and using such constructs. The traps may be used as therapeutic or diagnostic (imaging or non-imaging) agents for diseases/disorders caused by over-production/activity of the target ligand. In an embodiment of the invention there is provided a multivalent binding agent with affinity for a member of the TGF-? superfamily, the agent having the general structure I: (<bd1>-linker1)k-[{<bd1>-linker2-<bd2>-linker3f-}n-(<bd3>)m-(linker4-<bd4>)d]h, where: n and h are independently greater than or equal to 1; d, f, m and k are independently equal to or greater than zero; bd's are polypeptide binding domains having an affinity for the same member of the TGF-? superfamily; and, linkers are unstructured polypeptide sequences.Type: ApplicationFiled: October 18, 2012Publication date: April 11, 2013Inventors: Maureen D. O'Connor-McCourt, Traian Sulea, John C. Zwaagstra, Jason Baarsdsnes
-
Publication number: 20130089500Abstract: The invention provides multivalent ligand binding agents (traps) for members of the TGF-? superfamily and polypeptide linkers and methods for making and using such constructs. The traps may be used as therapeutic or diagnostic (imaging or non-imaging) agents for diseases/disorders caused by over-production/activity of the target ligand. In an embodiment of the invention there is provided a multivalent binding agent with affinity for a member of the TGF-? superfamily, the agent having the general structure I: (<bd1>linker1)k-[{<bd1>-linker2-<bd2>linker3f-}n-(<bd3>)m-(linker4-<bd4>)d]h, where: n and h are independently greater than or equal to 1; d, f, m and k are independently equal to or greater than zero; bd's are polypeptide binding domains having an affinity for the same member of the TGF-? superfamily; and, linkers are unstructured polypeptide sequences.Type: ApplicationFiled: October 18, 2012Publication date: April 11, 2013Inventors: Maureen D. O'Connor-McCourt, Traian Sulea, John C. Zwaagstra, Jason Baarsdness
-
Patent number: 8318135Abstract: The invention provides multivalent ligand binding agents (traps) for members of the TGF-? superfamily and polypeptide linkers and methods for making and using such constructs. The traps may be used as therapeutic or diagnostic (imaging or non-imaging) agents for diseases/disorders caused by over-production/activity of the target ligand.Type: GrantFiled: March 19, 2008Date of Patent: November 27, 2012Assignee: National Research Council of CanadaInventors: Maureen D. O'Connor-McCourt, Traian Sulea, John C. Zwaagstra, Jason Baardsnes
-
Publication number: 20110236309Abstract: The invention provides hetero-multivalent ligand binging agents (traps) for members of the TGF-? superfamily, as well as methods for making and using such constructs. In an embodiment of the invention there is provided a hetero-multivalent binding agent with affinity for a member of the TGF-? superfamily, said agent comprising the general structure (I): (<bd1>-linker1)k-[{<bd1>-linker2-<bd2>-linker3r-}n-(<bd3>)m-(linker4-<bd4>)d]h, where bd1, bd2, bd3 and bd4 are polypeptide binding domains having an affinity for different sites on the same member or for different members of the TGF-? superfamily, wherein at least two of bd1, bd2, bd3, and bd4 are different from each other.Type: ApplicationFiled: September 17, 2009Publication date: September 29, 2011Inventors: Maureen D. O'Connor-Mccourt, Traian Sulea, John C. Zwaagstra, Jason Baardsnes, Catherine Collins
-
Publication number: 20100120147Abstract: The invention provides multivalent ligand binging agents (traps) for members of the TGF-? superfamily and polypeptide linkers and methods for making and using such constructs. In an embodiment of the invention there is provided a multivalent binding agent with affinity for a member of the TGF-? superfamily, said agent comprising the general structure I: (<bd1>-linker1)k-[{bd1>-linker2-<bd2>-linker3f-}n-(<bd3>)m-(linker4-<bd4>)d]h, where: -n and h are independently greater than or equal to 1; -d, f, m and k arc independently equal to or greater than zero; -bd1, bd2, bd3 and bd4 are polypeptide binding domains having an affinity for the same member of the TGF-? superfamily, with bd1, bd2, bd3, and bd4 being independently the same or different from each other; and, -linkeri, linker2, linker3 and linker4 are unstructured polypeptide sequences; wherein the number of amino acids in each linker is determined independently and is greater than or equal to X/2.Type: ApplicationFiled: March 19, 2008Publication date: May 13, 2010Inventors: Maureen D. O'Connor-McCourt, Traian Sulea, John C. Zwaagstra, Jason Baardsnes